Amgen Inc. agreed to pay $3.7 billion in cash to acquire ChemoCentryx Inc., a biotech company with a recently approved drug to treat a rare immune-system disease.
Amgen said Thursday it will pay $52 a share for ChemoCentryx, more than twice the company’s share price at the close of trading on Wednesday.
Discussion about this post